[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"physiopathology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:physiopathology":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100505271",false,"NCT05859191","Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus","Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus","FiNKLUPUS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and\u002For secondary Gougerot-Sjögren's\n* Lupus patient, newly diagnosed or known, untreated or in relapse\n* Lupus patient considered stable by the treating practitioner\n* Requiring blood sampling for follow-up\n\nExclusion Criteria:\n\n* Main autoimmune disease other than lupus\n* Patient under legal protection, guardianship or curators\n* Opposition to data processing",true,"ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.",[25,26],"Systemic Lupus Erythematosus","Physiopathology",[28],"lupus","RECRUITING","2026-04-29",{"date":32,"type":33},"2026-04-30","ACTUAL",{"date":35,"type":33},"2023-07-21",{"date":37,"type":21},"2030-07",{"name":39,"class":40},"University Hospital, Tours","OTHER",1,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100605739","NCT07166432","Development, Application, and Mechanistic Investigation of a Novel Minimally-Invasive Bidirectional Epidural Cerebellar Stimulation Technique for Cerebellar Cognitive Affective Syndrome","Inclusion Criteria:\n\n* 1\\. Clinically and biochemically confirmed ACTH-dependent or ACTH-independent Cushing syndrome (loss of serum cortisol circadian rhythm, elevated 24-hour urinary free cortisol, and failure to suppress on low-dose dexamethasone suppression test).\n\n  2\\. Cranial MRI demonstrating unequivocal cerebellar atrophy (CCAS imaging criterion: cerebellar hemisphere or vermian volume ≥1.5 SD below age-matched normative data).\n\n  3\\. Established clinical diagnosis of CCAS (meets Schmahmann criteria, CCAS-S total score ≥20).\n\n  4\\. Cerebellar ataxia rating scale (SARATA) ≥10, indicating at least moderate motor ataxia.\n\n  5\\. Positive cognitive impairment screen (MoCA \\\u003C26, or Z-scores ≤-1.5 in at least two cognitive domains).\n\n  6\\. Willingness to undergo minimally invasive epidural cerebellar stimulation and provision of written informed consent.\n\nExclusion Criteria:\n\nPatients with significant systemic disease; occurrence of major complications or irreproducible, critical deviations in data collection or experimental procedures; or any circumstance rendering continued participation inappropriate-including clinical deterioration, serious adverse events, or poor compliance-will result in discontinuation of the subject's enrollment.","85 Years",{"count":49,"type":21},200,"Building on previous findings regarding microglial immune function and the immunosuppressive effects of glucocorticoids, this project centers on the cerebellum's role in cognitive science. Using Cushing's syndrome-induced cerebellar atrophy leading to CCAS as a model, we aim to elucidate the pathogenic mechanisms governed by the neuro-adrenal-immune network and to uncover the molecular basis by which a novel minimally invasive brain-machine fusion system ameliorates cerebellar ataxia and cognitive impairment.",[52,53,26],"Cerebellar Atrophy","Etiology","2025-09-03",{"date":56,"type":33},"2025-09-10",{"date":58,"type":33},"2025-06-28",{"date":60,"type":21},"2028-06-01",{"name":62,"class":40},"Peking University First Hospital",""]